Evidence map›Paper›PMID 34372565›Full record

ArticleViruses2021

Variant Analysis of SARS-CoV-2 Genomes from Belgian Military Personnel Engaged in Overseas Missions and Operations.

Jean-Paul Pirnay, Philippe Selhorst, Samuel L Hong, Christel Cochez, Barney Potter, Piet Maes, Mauro Petrillo, Gytis Dudas, Vincent Claes, Yolien Van der Beken and 16 more

Abstract read
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Jean-Paul PirnayLaboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, Belgium.ORCID 0000-0002-6863-5219
Philippe SelhorstUnit of Virology and Outbreak Research Team, Department of Biomedical Sciences, Institute of Tropical Medicine, 2000 Antwerp, Belgium.ORCID 0000-0002-4488-5790
Samuel L HongDepartment of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0001-6354-4943
Christel CochezLaboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, Belgium.
Barney PotterDepartment of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium.
Piet MaesDepartment of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium.
Mauro PetrilloEuropean Commission, Directorate-General Joint Research Centre (JRC), 21027 Ispra, Italy.ORCID 0000-0002-6782-4704
Gytis DudasGothenburg Global Biodiversity Centre, 413 19 Gothenburg, Sweden.ORCID 0000-0002-0227-4158
Vincent ClaesClinical Laboratory, Queen Astrid Military Hospital, 1120 Brussels, Belgium.ORCID 0000-0001-6398-4009
Yolien Van der BekenClinical Laboratory, Queen Astrid Military Hospital, 1120 Brussels, Belgium.
Gilbert VerbekenLaboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, Belgium.
Julie DegueldreClinical Laboratory, Queen Astrid Military Hospital, 1120 Brussels, Belgium.
Simon DellicourDepartment of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0001-9558-1052
Lize CuypersDepartment of Laboratory Medicine, UZ Leuven Hospital, 3000 Leuven, Belgium.ORCID 0000-0002-9433-8752
France T'SasClinical Laboratory, Queen Astrid Military Hospital, 1120 Brussels, Belgium.
Guy Van den EedeEuropean Commission, Directorate-General Joint Research Centre (JRC), 1050 Brussels, Belgium.
Bruno VerhasseltDepartment of Diagnostic Sciences, Ghent University Hospital, Ghent University, 9000 Ghent, Belgium.
Wouter WeutsQueen Astrid Military Hospital, 1120 Brussels, Belgium.
Cedric Smets14th Medical Battalion, 1800 Peutie, Belgium.
Jan MertensMedical Component, Ministry of Defense, 1140 Brussels, Belgium.
Philippe GeeraertsMedical Component, Ministry of Defense, 1140 Brussels, Belgium.
Kevin K AriënUnit of Virology, Department of Biomedical Sciences, Institute of Tropical Medicine, 2000 Antwerp, Belgium.
Emmanuel AndréDepartment of Laboratory Medicine, UZ Leuven Hospital, 3000 Leuven, Belgium.
Pierre NeirinckxMedical Component, Ministry of Defense, 1140 Brussels, Belgium.
Patrick SoentjensCenter for Infectious Diseases, Queen Astrid Military Hospital, 1120 Brussels, Belgium.
Guy BaeleDepartment of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-1915-7732

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More than a year after the first identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of the 2019 coronavirus disease (COVID-19) in China, the emergence and spread of genomic variants of this virus through travel raise concerns regarding the introduction of lineages in previously unaffected regions, requiring adequate containment strategies. Concomitantly, such introductions fuel worries about a possible increase in transmissibility and disease severity, as well as a possible decrease in vaccine efficacy. Military personnel are frequently deployed on missions around the world. As part of a COVID-19 risk mitigation strategy, Belgian Armed Forces that engaged in missions and operations abroad were screened (7683 RT-qPCR tests), pre- and post-mission, for the presence of SARS-CoV-2, including the identification of viral lineages. Nine distinct viral genotypes were identified in soldiers returning from operations in Niger, the Democratic Republic of the Congo, Afghanistan, and Mali. The SARS-CoV-2 variants belonged to major clades 19B, 20A, and 20B (Nextstrain nomenclature), and included "variant of interest" B.1.525, "variant under monitoring" A.27, as well as lineages B.1.214, B.1, B.1.1.254, and A (pangolin nomenclature), some of which are internationally monitored due to the specific mutations they harbor. Through contact tracing and phylogenetic analysis, we show that isolation and testing policies implemented by the Belgian military command appear to have been successful in containing the influx and transmission of these distinct SARS-CoV-2 variants into military and civilian populations.

Indexed as

Military PersonnelAfghanistanBelgiumChinaCOVID-19Democratic Republic of the CongoGenome, ViralGenomicsHumansMaliMolecular EpidemiologyMutationNigerPhylogenySARS-CoV-2TravelCOVID-19genomic epidemiologymilitaryoutbreakSARS-CoV-2variants

Identifiers

PMID34372565
PMCPMC8310367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.